{"id":"NCT04410198","sponsor":"FibroGen","briefTitle":"Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants","officialTitle":"A Phase 3b Multicenter, Open-Label Single Arm Study of Roxadustat: Either as Conversion From a Continuous Erythropoietin Receptor Activator (CERA), or as Initial Anemia Treatment in Hemodialysis (HD) Patients - DENALI Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-05-26","primaryCompletion":"2021-06-30","completion":"2021-10-11","firstPosted":"2020-06-01","resultsPosted":"2022-09-13","lastUpdate":"2022-09-13"},"enrollment":203,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia Associated With End Stage Renal Disease (ESRD)"],"interventions":[{"type":"DRUG","name":"Roxadustat","otherNames":[]}],"arms":[{"label":"Roxadustat","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and effectiveness of Roxadustat dosing regimens among chronic dialysis participants converted from ESA therapy or who are ESA-naïve.","primaryOutcome":{"measure":"Percentage of Participants With Mean Hb Value ≥10 g/dL","timeFrame":"Week 16 through Week 24","effectByArm":[{"arm":"Roxadustat","deltaMin":84.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":203},"commonTop":["Diarrhoea","Cough","COVID-19"]}}